After a positive test for COVID-19 earlier this month, Dr. Anthony Fauci said on Tuesday that he had joined a growing group of people who had experienced a bounce from Paxlovid after antiviral treatment at Pfizer.
Fauci, 81, said that when his first test was positive two weeks ago, he had some symptoms. However, when he felt worse, “due to [his] age,” he was prescribed Paxlovid.
In addition to fatigue and a little tension, Fauci said he “felt fine” and had a negative test in a quick test after a five-day course at Paxlovid.
After negative testing for three consecutive days, Fauci said he decided to take another caution test and was positive again on the fourth day. “It’s different from what people mean by Paxlovid reflection,” Fauci said in a distance interview at Tuesday’s Foreign Policy Global Health Forum.
The next day he started to feel “bad” and “worse than in the first round,” he added.
Paxlovid has been approved in the United States for people with mild to moderate symptoms of COVID-19 who are at increased risk of developing a serious illness.
Last month, the Centers for Disease Control and Prevention asked doctors to look out for a seemingly rare but increasingly reported occurrence.
“Paxlovid continues to be recommended for the treatment of mild to moderate early COVID-19 disease in people at high risk of developing serious disease,” the CDC wrote in a health alert.
A recurring phenomenon, described as recurrence of COVID-19 symptoms as the development of a new viral test positive after a negative test, was detected between two and eight days after the initial recovery. A brief recurrence of COVID-19 symptoms may be part of the virus’s “natural history,” officials said, and may occur in some people, regardless of Paxlovid treatment or vaccination status.
Last week, Fauci told reporters at the Covid-19 briefing at the White House that Paxlovid felt good after a positive test and first course.
“Everything is fine with Fauchi and thank you for asking,” Fauci said. “I’m vaccinated. I’ve doubled my progress. And I don’t think if I didn’t, I probably wouldn’t talk to you, now I think that’s what I look like.”
However, upon his return to COVID-19, Fauci was prescribed another Paxlovid course, he said. On Tuesday, he sat on the fourth day of the five-day course.
“I am already on the fourth day of the five-day course of my second course, Paxlovid. And fortunately I feel good. I mean, I’m not completely asymptomatic, but I’m sure I’m not.” he felt a great pain, “said Fauci. Healthcare professionals report that although information is still limited, available data suggest that most people who experience the rebound phenomenon are less likely to suffer from severe forms of the disease.
At this time, CDC states that there is currently no evidence that an additional treatment of Paxlovid, is needed, following a rebound.
The Food and Drug Administration also says that “there is no evidence of benefit at this time for a longer course of treatment … or repeating a treatment course of Paxlovid in patients with recurrent COVID-19 symptoms following completion of a treatment course.”
The CDC currently recommends that doctors advise their patients with COVID-19 rebound to follow CDC’s guidance on isolation and take additional precautions to prevent transmission.
Patients must be re-isolated for at least five days, and for one visit to the surgery, their period of loneliness may end after five full days if the fever disappears within 24 hours and the symptoms improve, says the CDC. Doctors are also advised to tell their patients to wear a mask for a total of 10 days after the symptoms of the rebound phenomenon begin, the authority said.
“Even if a patient is being treated with an antiviral drug, the risk of transmission during the rebound phenomenon of COVID-19 can be managed by following the CDC’s guidelines on loneliness, including taking additional precautions. Such as masks,” the agency wrote in May.
Earlier this month, Pfizer also announced new clinical trials that show that Paxlovid significantly reduces the risk of hospitalization or death in people at moderate risk of developing serious illness. However, the company claims that the treatment is still good for people at risk.